FDA authorizes sale of Zyn nicotine pouches, saying public health benefits outweigh risk
Zyn and the retailers who sell the product have run afoul of regulators in recent years. The FDA in April of last year warned 119 retailers to stop selling Zyn to underage people, and the company was ordered to pay $1.2 million last year for violating Washington, D.C.’s smokeless tobacco ban.
Altria Group stock outperformed the S&P 500 over the past year (total return), something you don't hear about so often. See ...
Despite the seemingly restrictive nature of the FDA's proposed ruling, I remain highly optimistic about the resilience and ...
Officials proposed limiting the amount of nicotine to make cigarettes less addictive, but it's unclear if the incoming ...
U.S. regulators are proposing to cap the amount of nicotine in cigarettes at non-addictive levels, in a potential world-first ...
Discover why Altria may be a strong investment opportunity, with potential for significant total returns and a possible ...
A proposed FDA rule would set nicotine levels on tobacco products at less than half the current average and could save ...
Hosted on MSN52m
Altria (MO) Outperforms Broader Market: What You Need to KnowThe latest trading session saw Altria (MO) ending at $51.86, denoting a +1.37% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 1%. On the other hand, the Dow ...
In a report released today, Eric Serotta from Morgan Stanley maintained a Hold rating on Altria Group (MO – Research Report), with a price ...
brand E-vapor products under the NJOY ACE brand It is also one of the world’s largest producers and marketers of medical products in the treatment of illnesses caused by tobacco. Altria sells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback